Browse 113 bipolar disorder clinical trials enrolling across the United States and Canada. 83 people applied to bipolar disorder studies last month. Search by city or state to find one near you.
Bipolar disorder is marked by swings between mania and depression, and for most people the depressive episodes are the longest and hardest part. Standard antidepressants on their own can trigger mania, so bipolar depression needs its own treatments, and there are still relatively few. Many people try several medicines before finding one that works with tolerable side effects.
Sponsor: Weill Medical College of Cornell University
Sex: All
Age: 18 - 70
Code: NCT07680153
Recruiting
Transition Care for FEP
for
Schizoaffective Disorders,
Location: Harvey IL
Sponsor: University of Chicago
Sex: All
Age: 18 - 40
Code: NCT07713849
Recruiting
CBT-CP for Veterans With SMI
for
Chronic Pain, Schizophrenia, Psychotic Disorders,
Location: Baltimore MD
Sponsor: VA Office of Research and Development
Sex: All
Age: 18+
Code: NCT06758414
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
for
Bipolar Disorder
Location: Watertown MA, Springfield MA, New Haven CT,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07286175
Phase 2, Recruiting
Visual Perception in Schizophrenia
for
Schizophrenia Disorders, Bipolar Disorder,
Location: Rochester NY
Sponsor: University of Rochester
Sex: All
Age: 18 - 65
Code: NCT06911931
Recruiting
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
for
Bipolar Disorder
Location: Los Alamitos CA
Sponsor: AbbVie
Sex: All
Age: 18 - 65
Code: NCT07071532
Phase 1, Recruiting
Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder
for
Bipolar Disorder
Location: Cleveland OH
Sponsor: University Hospitals Cleveland Medical Center
Sex: All
Age: 18+
Code: NCT03829787
Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor